Approval · Notice of Compliance 823 · 2001
ASACOL: Notice of Compliance 823
Issued September 21, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 823
- Date
- September 21, 2001
- Company
- Procter & Gamble Pharmaceuticals Canada, IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: maintenance of remission of mild to moderate ulcerative colitis
- Therapeutic class
- Lower gastrointestinal anti-inflammatory
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ASACOL | Not yet assigned | — |
Medicinal ingredients
- MESALAZINE 400 MG per TAB